Delivery Order SPE2DB22D2206-SPE2DB25FJG72
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of AmBisome 50 mg vials, a critical antifungal medication used in military and federal healthcare systems. This competitively awarded, non-set-aside contract is valued at $16,184.74 with a firm fixed price structure and an ultimate completion date of August 5, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 1, 2025, for the supply of AmBisome 50 mg vials, a specialized antifungal pharmaceutical product. This competitively awarded, non-set-aside contract carries a ceiling value of $7,741.00 with firm fixed pricing and an ultimate completion date of September 2, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,906.55 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of AmBisome 50 mg vials. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. AmBisome is an antifungal medication used to...
- The Defense Logistics Agency awarded a $14.7K delivery order to AmerisourceBergen Drug Corp for 50 mg vials of AmBisome, an antifungal medication used for serious systemic fungal infections. The contract, awarded on July 24, 2025, with completion targeted for July 25, 2025, utilizes firm fixed pricing with no set-aside designation. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's existing...
- Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, has been awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical in the amount of $2,517.84. This contract is for the delivery of 50 mg vials of AmBisome, a specialty pharmaceutical product. The contract has a completion date of February 16, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor providing...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $2,098.20 order is for the supply of the antifungal medication AMBISOME 50 MG VIALS. This delivery order is part of a larger indefinite delivery contract (IDC) between DLA Troop Support Medical and Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 50 mg vials of the pharmaceutical product AmBisome. The contract has a completion date of February 16, 2024 and a potential value of $2,517.84. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $1,975.20 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4559476979 AMBISOME 50 MG VIALS. This contract has an ultimate completion date of January 3, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a for-profit pharmaceutical distribution company, to provide AmBisome 50 mg vials. The contract has a ceiling value of $2,517.84 and a performance period through March 28, 2024. AmerisourceBergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary contract vehicle for the company to...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distributor, to provide AMBISOME 50 MG VIALS. The order has a potential value of $6,210.92 and a completion date of February 22, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, serves as the prime contractor. This award is part of a larger indefinite delivery contract (IDC) valued at up to...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJG72Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of AmBisome 50 mg vials, a specialized pharmaceutical product used in military and federal healthcare systems. This firm fixed-price delivery order, valued at $11,016.77, was competitively awarded without set-aside designation and is scheduled for completion by August 8, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive prime vendor contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices—to support military healthcare programs globally. The parent IDC demonstrates the company's established capability to serve as a critical vendor for the Defense Health Agency and other federal healthcare systems through a flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 8/7/25 |